ASCO GU 2018: Survival Outcomes of Pre-Metastatic Castration-Resistant Prostate Cancer and the Burden of Developing Metastasis: A Systematic Literature Review
San Francisco, CA (UroToday.com) Medical castration, or more rarely surgical castration, has become the mainstay of therapy for metastatic prostate cancer following definitive primary therapy or for de novo metastatic disease. However, unfortunately, all men eventually develop resistance and progress.
ASCO GU 2018: An Observational Study Profiling Biospecimens from 10,000 Metastatic Prostate Cancer Patients to Screen for Molecular Alterations
San Francisco, CA (UroToday.com) Despite recent success in development and use of targeted agents in patients with solid tumors, there is a paucity of such therapies approved for use in prostate cancer (PC). The authors presented this observational study performing next-generation sequencing (NGS) to men with metastatic PC, in an attempt to evaluate the proportion of patients available for targeted therapy clinical trials in metastatic PC. Furthermore, they aimed to assess the feasibility of using a large-scale NGS screening program to match patients for eligibility criteria in clinical trials.
ASCO GU 2018: Real-World Experience with Docetaxel for Castration-Sensitive Prostate Cancer from a Population-Based Analysis
San Francisco, CA (UroToday.com) Phase III clinical trials have demonstrated efficacy with an overall survival (OS) benefit for the addition of docetaxel (DOC) to androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The clinical effectiveness of DOC with ADT in the general patient population remains undefined.
ASCO GU 2018: Best of Journals: Prostate Cancer - Medical Oncology
San Francisco, CA (UroToday.com) Dr. de Bono provided a summary of the key publications from a medical oncology perspective for the year 2017. He focused on 3 specific areas: Germline DNA testing, Somatic DNA testing, and Treating Advanced Disease. Below are the highlights of each section, with appropriate references listed below.
ASCO GU 2018: Interim analysis of a prospective randomized trial of dietary carbohydrate restriction for men with a rising PSA after failed primary treatment: Carbohydrate and Prostate Study 2
San Francisco, CA (UroToday.com) As clinicians, we often get asked about dietary modifications or lifestyle modifications that may help prevent and improve prostate cancer. However, there has been very little data to support any dietary supplement / vitamins in reducing the risk of prostate cancer or improving outcomes.
ASCO GU 2018: A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer
San Francisco, CA (UroToday.com) Androgen-axis inhibitors, specifically enzalutamide and abiraterone, have revolutionized the management of advanced prostate cancer. However, despite their efficacy, all men eventually develop resistance and progress. Identification of these resistance mechanisms may enable development of therapies to resensitize PCa to these agents, thereby delaying the need for secondary treatments.
ASCO GU 2018: Comparative Assessment of Abiraterone or Enzalutamide Activity in the PROREPAIR-B Study
San Francisco, CA (UroToday.com) Dr. Lozano and colleagues presented their comparative assessment of abiraterone or enzalutamide activity in the PROREPAIR-B study. Germline mutations in DNA repair genes have been associated with poor prostate cancer outcomes in retrospectives studies [1,2]; these defects have been identified in 12% of mCRPC patients . Germline and somatic DNA damage repair defects (DDR) have been correlated with response to platinum-based chemotherapy and PARP inhibitors [4,5], but no conclusive data are available with regards to currently approved therapies for mCRPC. As such, the objective of this study was to assess the outcomes of mCRPC patients in the PROREPAIR-B study using currently approved, standard treatment agents, abiraterone or enzalutamide.